CS-003 Free base

Cat. No.:	HY-19633
CAS No.:	191672-52-3
Molecular Formula:	$C_{34}H_{38}Cl_2N_2O_6S$
Molecular Weight:	673.65
Target:	Neurokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CS-003 Free base (CS-003), a triple tachykinin receptor antagonist, shows high affinities for human (Neurokinin) NK1, NK2 and NK3 receptors with K_i values of 2.3 nM, 0.54 nM and 0.74 nM, respectively. CS-003 Free base (CS-003) has therapeutic efficacy on respiratory diseases associated with neurokinins.		
IC_{50} & Target	NK1 2.3 nM (Ki)	NK2 0.54 nM (Ki)	NK3 0.74 nM (Ki)
In Vitro	CS-003 (0.01-10 μM; 24 hours) inhibits NK1, NK2 or NK3 induced inositol phosphate formation in a concentration-dependent manner with pA2 values of 8.7, 9.4 and 9.5 μM, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	CS-003 (intravenous injection; 0.01-3.0 mg/kg; 5 min before neurokinin A/B/C injection) inhibits substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID_{50} values of 0.13, 0.040 and 0.063 mg/kg, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Tsuchida H, et al. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses. Eur J Pharmacol. 2008 May 31;586(1-3):306-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA